GSK (GSK)
| Bid | 35.69 |
| Market Cap | 71.56B |
| Revenue (ttm) | 31.38B |
| Net Income (ttm) | 2.58B |
| EPS (ttm) | 1.6 |
| PE Ratio (ttm) | 22.03 |
| Forward PE | 8.66 |
| Analyst | Hold |
| Ask | 35.74 |
| Volume | 5,464,958 |
| Avg. Volume (20D) | 5,531,503 |
| Open | 34.78 |
| Previous Close | 34.64 |
| Day's Range | 34.73 - 35.45 |
| 52-Week Range | 31.72 - 45.93 |
| Beta | 0.30 |
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines ...
Analyst Forecast
According to 4 analyst ratings, the average rating for GSK stock is "Hold." The 12-month stock price forecast is $47, which is an increase of 33.35% from the latest price.
Stock Forecasts
3 days ago · https://www.marketscreener.com
Investing in the $532B Oncology Boom: Key Stocks Shaping the Future of Cancer TreatmentThe global oncology drug market, valued at over $200 billion today, is on pace to reach $532 billion by 2031-a growth story driven not just by rising demand but by genuine innovation. After years of i...
4 days ago · proactiveinvestors.co.uk
AstraZeneca and GSK retain defensive qualities, but tariff assault on sector could change thatUBS has warned that drugmakers such as AstraZeneca and GSK could be among the most exposed in Europe's pharmaceuticals sector should President Trump follow through on threats to impose new levies on t...
